**Supplementary table 3. Statistical analyses in 99 adults with primary antibody deficiency.**

|  |
| --- |
| **Comparisons between referring doctor types** |
| *Variable* | *Category* | *GP* | *Internist* | *Pulmonologist* | *Other* | *p-value* |
| Diagnosis | CVIDunPAD | 3 (9%)32 (91%) | 3 (20%)12 (80%) | 3 (7%)40 (93%) | 1 (17%)5 (83%) | 0.06 |
| HRCT bronchialwall thickening | NoYes | 9 (50%)9 (50%) | 5 (56%)4 (44%) | 16 (52%)15 (48%) | 1 (50%)1 (50%) | 1.00 |
| HRCT bronchiectasis | 0/1 lobes2+ lobes | 14 (78%)4 (22%) | 8 (89%)1 (11%) | 16 (52%)15 (48%) | 2 (100%)0 (0%) | 0.08 |
| HRCT mucus plugging | NoYes | 16 (89%)2 (11%) | 8 (89%)1 (11%) | 24 (77%)7 (23%) | 1 (50%)1 (50%) | 0.41 |
| HRCT atelectasis | NoYes | 15 (83%)3 (17%) | 9 (100%)0 (0%) | 24 (77%)7 (23%) | 2 (100%)0 (0%) | 0.50 |
| **Comparisons between patient diagnoses** |
| *Variable* | *Category* | *CVID* | *unPAD* | *p-value* |
| HRCT bronchial wall thickening | NoYes | 3 (43%)4 (57%) | 28 (53%)25 (47%) | 0.62 |
| HRCT bronchiectasis | 0/1 lobes2+ lobes | 6 (86%)1 (14%) | 34 (64%)19 (36%) | 0.26 |
| HRCT mucus plugging | NoYes | 7 (100%)0 (0%) | 42 (79%)11 (21%) | 0.18 |
| HRCT atelectasis | NoYes | 7 (100%)0 (0%) | 43 (81%)10 (19%) | 0.21 |
| Therapy (related to antibody deficiency diagnosis) | NoneAntibiotic prophylaxisIVIG or SCIG | 0 (0%)1 (10%)9 (90%) | 50 (56%)19 (21%)20 (22%) | **<0.001** |
| **Differences between patients receiving different therapies** |
| *Variable* | *Category* | *None* | *Antibiotic prophylaxis* | *IVIG or SCIG* | *p-value* |
| HRCT bronchial wall thickening | NoYes | 10 (42%)14 (58%) | 8 (57%)6 (43%) | 13 (59%)9 (41%) | 0.51 |
| HRCT bronchiectasis | 0/1 lobes2+ lobes | 16 (67%)8 (33%) | 7 (50%)7 (50%) | 17 (77%)5 (23%) | 0.27 |
| HRCT mucus plugging | NoYes | 20 (83%)4 (17%) | 10 (71%)4 (29%) | 19 (86%)3 (14%) | 0.58 |
| HRCT atelectasis | NoYes | 19 (79%)5 (21%) | 11 (79%)3 (21%) | 20 (91%)2 (9%) | 0.50 |
| **Comparison of genders** |
| *Variable* | *Category* | *Males* | *Females* | *p-value* |
| Diagnosis | CVIDUnPAD | 5 (18%)23 (82%) | 5 (7%)66 (93%) | 0.17 |
| HRCT bronchial wall thickening | NoYes | 9 (43%)8 (47%) | 22 (51%)21 (49%) | 1.00 |
| HRCT bronchiectasis | 0/1 lobes2+ lobes | 10 (59%)7 (41%) | 30 (70%)13 (30%) | 0.55 |
| HRCT mucus plugging | NoYes | 13 (76%)4 (24%) | 36 (84%)7 (16%) | 0.71 |
| HRCT atelectasis | NoYes | 13 (76%)4 (24%) | 37 (86%)6 (14%) | 0.45 |
| Therapy (related to antibody deficiency diagnosis) | NoneAntibiotic prophylaxisIVIG or SCIG | 11 (39%)7 (25%)10 (36%) | 39 (55%)13 (19%)19 (27%) | 0.37 |
| **Differences between most important complaint categories** |
| *Variable* | *Category* | *ENT/airway/cough* | *Tired/other* | *p-value* |
| Always ill | NoYes | 4 (8%)44 (92%) | 7 (14%)43 (86%) | 0.53 |
| HRCT bronchial wall thickening | NoYes | 16 (50%)16 (50%) | 14 (52%)3 (48%) | 1.00 |
| HRCT bronchiectasis | 0/1 lobes2+ lobes | 20 (62%)12 (38%) | 19 (70%)8 (30%) | 0.59 |
| HRCT mucus plugging | NoYes | 23 (72%)9 (28%) | 25 (93%)2 (7%) | **0.05** |
| HRCT atelectasis | NoYes | 26 (81%)6 (19%) | 23 (85%)4 (15%) | 0.74 |
| Gender | MaleFemale | 12 (25%)36 (75%) | 16 (32%)34 (68%) | 0.51 |
| **Associations with being always ill** |
| *Variable* | *Category* | *Not always ill* | *Always ill* | *p-value* |
| HRCT bronchial wall thickening | NoYes | 1 (20%)4 (80%) | 29 (54%)25 (46%) | 0.20 |
| HRCT bronchiectasis | 0/1 lobes2+ lobes | 4 (80%)1 (20%) | 35 (65%)19 (35%) | 0.65 |
| HRCT mucus plugging | NoYes | 5 (100%)0 (0%) | 43 (80%)11 (20%) | 0.57 |
| HRCT atelectasis | NoYes | 5 (100%)0 (0%) | 44 (81%)10 (19%) | 0.58 |
| Gender | MaleFemale | 4 (36%)7 (64%) | 24 (28%)63 (72%) | 0.51 |
| **Associations with presence of ≥1 of red/swollen joints and/or pain in bones/joints** |
| *Variable* | *Category* | *Absence* | *Presence* | *p-value* |
| Always ill | NoYes | 4 (15%)23 (85%) | 7 (10%)64 (90%) | 0.49 |
| HRCT bronchial wall thickening | NoYes | 8 (53%)7 (47%) | 22 (50%)22 (50%) | 1.00 |
| HRCT bronchiectasis | 0/1 lobes2+ lobes | 9 (60%)6 (40%) | 30 (68%)14 (32%) | 0.75 |
| HRCT mucus plugging | NoYes | 10 (67%)5 (33%) | 38 (86%)6 (14%) | 0.13 |
| HRCT atelectasis | NoYes | 11 (87%)4 (13%) | 38 (86%)6 (14%) | 0.25 |
| Most important complaint | Ear/airway/coughTired/other | 17 (63%)10 (37%) | 31 (44%)40 (56%) | 0.11 |
| Gender | MaleFemale | 11 (41%)16 (59%) | 17 (24%)54 (76%) | 0.13 |
| **Associations with ≥1 of coughing productive, surgery chronic sinusitis, sinusitis nowadays, otitis nowadays, sinusitis in the past, otitis in the past** |
| *Variable* | *Category* | *Absence* | *Presence* | *p-value* |
| Always ill | NoYes | 5 (36%)9 (64%) | 6 (7%)78 (93%) | **0.008** |
| HRCT bronchial wall thickening | NoYes | 4 (40%)6 (60%) | 26 (53%)23 (47%) | 0.51 |
| HRCT bronchiectasis | 0/1 lobes2+ lobes | 7 (70%)3 (30%) | 32 (65%)17 (35%) | 1.00 |
| HRCT mucus plugging | NoYes | 8 (80%)2 (20%) | 40 (82%)9 (18%) | 1.00 |
| HRCT atelectasis | NoYes | 9 (90%)1 (10%) | 40 (82%)9 (18%) | 1.00 |
| Most important complaint | Ear/airway/coughTired/other | 5 (%)9 (64%) | 43 (51%)41 (49%) | 0.39 |
| Gender | MaleFemale | 3 (21%)11 (79%) | 25 (30%)59 (70%) | 0.75 |
| **Associations with season of the year with most complaints** |
| *Variable* | *Category* | *Spring - summer* | *Autumn - winter* | *p-value* |
| Family history of allergy | NoYes | 8 (27%)22 (73%) | 18 (27%)48 (73%) | 1.00 |
| HRCT bronchial wall thickening | NoYes | 7 (44%)9 (56%) | 21 (51%)20 (49%) | 0.77 |
| HRCT bronchiectasis | 0/1 lobes2+ lobes | 11 (69%)5 (31%) | 28 (68%)13 (32%) | 1.00 |
| HRCT mucus plugging | NoYes | 12 (75%)4 (25%) | 34 (83%)7 (17%) | 0.48 |
| HRCT atelectasis | NoYes | 13 (81%)3 (19%) | 35 (85%)6 (15%) | 0.70 |
| **Comparison of TAAQOL domains between Dutch reference population and Care Path data** |
| *Domain* | *Reference data* | *Care Path data* | *p-value* |
| Gross motor functioningFine motoric functioningCognitive functioningSleepPainSocial functioningDaily activitiesSexualityVitalityPositive emotionsDepressive emotionsAggressive emotions | 100 [81, 100]100 [100, 100]93 [75, 100]81 [56, 94]81 [63, 94]88 [75, 100]100 [75, 100]100 [75, 100]67 [50, 83]67 [58, 75]83 [67, 92]89 [78, 100] | 63 [25, 88]100 [75, 100]63 [31, 100]56 [31, 81]50 [38, 75]81 [63, 100]50 [25, 88]88 [50, 100]29 [8, 50]50 [33, 67]75 [50, 83]89 [67, 100] | **<0.001****<0.001****<0.001****<0.001****<0.001** **0.002****<0.001** **0.002****<0.001****<0.001****<0.001**0.01 |
| **Associations with ANA positivity** |
| *Variable* | *Category* | *ANA negative* | *ANA positive* | *p-value* |
| Bone / joint pain | NoYes | 20 (27%)55 (73%) | 3 (23%)10 (77%) | 1.00 |
| Fine motor skills | - | 100 [75, 100] | 100 [75, 100] | 0.97 |
| Family history of thyroid disease | NoYes | 48 (64%)27 (36%) | 8 (62%)5 (39%) | 1.00 |
| Age | - | 52.1 ± 15.6 | 48.2 ± 16.4 | 0.40 |
| Gender | MaleFemale | 21 (28%)54 (72%) | 4 (29%)10 (71%) | 1.00 |
| **Associations with Rheumatoid factor positivity** |
| *Variable* | *Category* | *RF negative* | *RF positive* | *p-value* |
| ANA | NegativePositive | 26 (87%)4 (13%) | 3 (75%)1 (25%) | 0.49 |
| Bone / joint pain | NoYes | 1 (3%)29 (97%) | 1 (25%)4 (75%) | 0.23 |
| Fine motor skills | - | 88 [50, 100] | 78 [53, 91] | 0.56 |
| Family history of thyroid disease | NoYes | 19 (63%)11 (37%) | 3 (75%)1 (25%) | 1.00 |
| Age | - | 56.6 ± 14.5 | 67.0 ± 6.9 | 0.17 |
| Gender | MaleFemale | 6 (25%)24 (80%) | 1 (25%)3 (75%) | 1.00 |
| **Associations with IgE Class 4-6 (IgE positive)** |
| ANA | NegativePositive | 51 (85%)9 (15%) | 4 (57%)3 (43%) | 0.10 |
| Rheumatoid factor | NegativePositive | 23 (96%)1 (4%) | 1 (100%)0 (0%) | 1.00 |
| Bone / joint pain | NoYes | 18 (30%)42 (70%) | 2 (25%)6 (75%) | 1.00 |
| Fine motor skills | - | 100 [84, 100] | 100 [94, 100] | 0.38 |
| Family history of thyroid disease | NoYes | 38 (63%)22 (37%) | 6 (75%)2 (25%) | 0.70 |
| Age | - | 50.4 ± 15.3 | 42.4 ± 15.8 | 0.17 |
| Gender | MaleFemale | 16 (26%)45 (74%) | 3 (37%)5 (63%) | 0.66 |

Abbreviations: ANA = antinuclear antibody, CVID = common variable immunodeficiency disorders, GP = general practitioner, HRCT = high resolution computed tomography, Ig = immunoglobulin, IVIG = intravenous immunoglobulin, RF = rheumatoid factor, SCIG = subcutaneous immunoglobulin, TAAQOL = TNO-AZL Questionnaire for Adult Health-Related Quality of Life [https://www.tno.nl/media/4727/vragenlijsten\_01032012.pdf; accessed June 2017], unPAD = unclassified antibody deficiency according to European Society for Immunodeficiencies (ESID) Registry criteria [https://esid.org/Working-Parties/Registry/Diagnosis-criteria; accessed June 2017]. P-values in bold are considered significant (<0.01).